How Drugs Work: A Molecular Perspective
Pharmacology is the science of how drugs interact with biological systems to produce their effects. At its core, pharmacology is applied chemistry: a drug is a molecule that binds to a specific biological target and alters its function. Understanding the chemistry of drugs reveals not only how they treat disease but also why they have side effects, why some people respond differently than others, and how new medicines are designed.
Drug Targets: What Molecules Do Drugs Act On?
Most drugs exert their effects by binding to one of four major classes of targets:
- Receptors: proteins that normally bind endogenous ligands (neurotransmitters, hormones). Drugs that activate receptors are agonists; those that block them are antagonists.
- Enzymes: drugs can inhibit enzyme activity (e.g., ACE inhibitors for hypertension, statins for cholesterol).
- Ion channels: drugs can block or modulate channel opening (e.g., local anesthetics block Na⁺ channels; calcium channel blockers treat angina).
- Transporters: drugs can block reuptake transporters (e.g., SSRIs block the serotonin transporter; cocaine blocks dopamine, norepinephrine, and serotonin transporters simultaneously).
Structure-Activity Relationships (SAR)
The structure-activity relationship (SAR) describes how changes in a molecule's chemical structure affect its biological activity. Drug design is fundamentally an exercise in molecular optimization:
- Steric factors: molecular size and shape determine whether the drug fits the binding pocket
- Functional groups: hydroxyl (–OH), amine (–NH₂), carboxyl (–COOH) groups form hydrogen bonds, ionic interactions, or covalent bonds with target residues
- Lipophilicity: a drug must be soluble enough to be absorbed but lipophilic enough to penetrate membranes. The partition coefficient (log P) quantifies this balance.
- Chirality: many drugs have chiral centers (asymmetric carbons), and enantiomers can have vastly different pharmacological properties. Thalidomide's tragedy — where one enantiomer was sedative and the other teratogenic — underscores the importance of stereochemistry.
Pharmacokinetics: ADME
Pharmacokinetics describes what the body does to a drug — how it is Absorbed, Distributed, Metabolized, and Eliminated (ADME).
Absorption
A drug must reach the bloodstream to have systemic effects. Oral drugs must survive the acid of the stomach (pH ~2), resist intestinal enzymes, and cross the intestinal epithelium. Lipid-soluble drugs cross more easily than hydrophilic ones.
Bioavailability (F) is the fraction of administered drug that reaches systemic circulation unchanged. Intravenous (IV) injection gives F = 100%. Oral drugs may have much lower bioavailability due to incomplete absorption and the first-pass effect (hepatic metabolism before reaching circulation).
Distribution
Once in the blood, drugs distribute into tissues. The volume of distribution (Vd) measures how extensively a drug distributes. A very lipophilic drug like chlorpromazine (antipsychotic) has a huge Vd (thousands of liters), meaning it concentrates heavily in tissues. Hydrophilic drugs stay closer to plasma.
Many drugs bind to plasma proteins (especially albumin). Only the free fraction is pharmacologically active. Drug-drug interactions can displace drugs from plasma proteins, suddenly increasing free drug levels.
The blood-brain barrier (BBB) — formed by tight junctions between brain endothelial cells — restricts entry of hydrophilic molecules. CNS-active drugs must either be lipophilic, small, or use specific transporters. L-DOPA exploits the large neutral amino acid transporter to enter the brain.
Metabolism
Most drug metabolism occurs in the liver via cytochrome P450 (CYP450) enzymes — a superfamily of heme-containing monooxygenases. CYP enzymes oxidize drugs to make them more hydrophilic and easier to excrete (Phase I reactions). Phase II reactions (conjugation with glucuronic acid, sulfate, glutathione) further increase hydrophilicity.
Critical interactions arise when multiple drugs compete for the same CYP enzyme: - CYP inhibitors (e.g., grapefruit juice flavonoids) can cause dangerous accumulation of co-administered drugs - CYP inducers (e.g., rifampicin for TB) can reduce blood levels of other drugs to sub-therapeutic concentrations
Some drugs are prodrugs — inactive precursors that are converted to the active form by metabolism. Codeine is O-demethylated to morphine by CYP2D6; individuals lacking CYP2D6 (poor metabolizers) receive no pain relief from codeine.
Elimination
Drugs and their metabolites are primarily excreted by the kidneys (in urine) or in bile (via the gut). The half-life (t₁/₂) is the time for the plasma concentration to decrease by 50%. After 4–5 half-lives, a drug is essentially eliminated from the body.
Renal impairment slows elimination of renally-cleared drugs, requiring dose adjustment to avoid toxicity.
Drug-Receptor Interactions: Agonists and Antagonists
Agonists
An agonist binds to a receptor and activates it, mimicking the endogenous ligand. Morphine is a full agonist at μ-opioid receptors, producing analgesia, sedation, and respiratory depression. Salbutamol (albuterol) is a β₂-adrenergic agonist that relaxes bronchial smooth muscle in asthma.
Antagonists
An antagonist binds but does not activate the receptor — it blocks the endogenous ligand or another drug. Propranolol blocks β-adrenergic receptors (beta-blocker) to reduce heart rate and blood pressure. Naloxone competitively antagonizes opioid receptors.
Partial Agonists
A partial agonist activates the receptor but to a submaximal degree even when all receptors are occupied. Buprenorphine (used for opioid use disorder) is a partial μ-opioid agonist — it reduces cravings and withdrawal with a ceiling effect that limits overdose risk.
Enzyme Inhibition as Drug Mechanism
Many drugs are enzyme inhibitors designed with high specificity.
- Statins (e.g., atorvastatin): competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Statins contain a structural moiety mimicking the transition state of the enzyme reaction.
- ACE inhibitors (e.g., enalapril): block angiotensin-converting enzyme, preventing conversion of angiotensin I to the vasoconstrictive angiotensin II, lowering blood pressure.
- Antibiotics: many target bacterial enzymes with no human counterpart. Penicillin irreversibly inhibits transpeptidase (penicillin-binding proteins), preventing bacterial cell wall cross-linking. Metronidazole is reduced by bacterial enzymes to a reactive nitroso radical that damages DNA.
- Tyrosine kinase inhibitors: imatinib (Gleevec) was developed to block the BCR-ABL kinase produced by the Philadelphia chromosome translocation in chronic myeloid leukemia — a landmark example of rational, mechanism-based drug design.
Pharmacodynamics: Dose-Response Relationships
Pharmacodynamics describes what a drug does to the body. The dose-response curve relates drug concentration to effect, typically sigmoidal when plotted on a log scale.
Key parameters: - EC₅₀: concentration producing 50% of maximal effect (relates to potency) - Emax: maximal effect achievable - Therapeutic index (TI) = TD₅₀ / ED₅₀: the ratio of toxic to effective dose. Drugs with narrow therapeutic indices (e.g., lithium, warfarin, digoxin) require careful monitoring.
Drug Resistance
Antimicrobial and anticancer drug resistance are major global health challenges. Resistance mechanisms include: - Target mutation: altered drug-binding site (e.g., EGFR T790M mutation in lung cancer) - Drug efflux pumps: ABC transporters actively export drugs from cells - Drug inactivation: β-lactamase enzymes hydrolyze the β-lactam ring of penicillin-class antibiotics - Target overexpression: cancer cells amplify the gene encoding the drug target
The chemistry of pharmacology thus intersects with evolutionary biology, structural biology, and genetics — a field in continuous development as pathogens evolve and new therapeutic targets are discovered.